A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn't live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens.
Researchers at MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type.
A study of patients with gynecologic cancers in Brazil found that most patients present with advanced disease, which leads to lower survival rates.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published a study in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.
Study: Young people using e-cigarettes are three times more likely to become daily cigarette smokers
An analysis of a large nationally representative longitudinal study by University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science found that starting tobacco products, including e-cigarettes, before the age of 18 is a major risk factor for people becoming daily cigarette smokers.
A study funded by Cancer Research UK shows that the immune response to COVID-19 is the same in people with solid tumors compared to those without cancer.
Researchers from the University of Cincinnati have identified a framework that could help people with serious health conditions keep up their lung cancer screening appointments during the current surge.
Scientists at the USC Center for Genetic Epidemiology and the Institute for Cancer Research, London, led a study that brings together data from the majority of genomic prostate cancer studies globally.
The National Comprehensive Cancer Network published two new Guidelines for Patients on healthy living and managing late and long-term side effects, and include appropriate ongoing screening for recurrence.
Researchers from SWOG Cancer Research Network have demonstrated that a triple drug combination—of irinotecan, cetuximab, and vemurafenib—is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.
